Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus

Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus

Glucagon-like peptide 1 (GLP-1) is secreted from enteroendocrine L-cells in response to oral nutrient intake and elicits glucose-stimulated insulin secretion while suppressing glucagon secretion. It also slows gastric emptying, which contributes to decreased postprandial glycemic excursions. In the...

Full description

Bibliographic Details
Main Authors: Young Min Cho, Rhonda D. Wideman, Timothy J. Kieffer
Format: Article
Language:English
Published: Academya Publishing Co. 2013-12-01
Series:Endocrinology and Metabolism
Subjects:
Glucagon-like peptide 1
Diabetes mellitus, type 2
Exenatide
Liraglutide
Exenatide long acting release
Online Access:http://e-enm.org/Synapse/Data/PDFData/2008ENM/enm-28-262.pdf

Internet

http://e-enm.org/Synapse/Data/PDFData/2008ENM/enm-28-262.pdf

Similar Items